证券代码：836433 证券简称：大唐药业 公告编号：2023-001 内蒙古大唐药业股份有限公司 第三届董事会第十次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2023 年 1 月 3 日 2.会议召开地点：公司会议室 3.会议召开方式：现场与网络相结合方式 4.发出董事会会议通知的时间和方式：2022 年 12 月 30 日以电子邮件方式发 出 5.会议主持人：董事长郝艳涛先生 6.会议列席人员：公司监事 7.召开情况合法、合规、合章程性说明： 会议的召集、召开和表决程序符合有关法律、法规及《公司章程》的有关规 定。 （二）会议出席情况 会议应出席董事 8 人，出席和授权出席董事 8 人。 董事朱贺年、张振华、谢晓燕、张剑因疫情防控原因以通讯方式参与表决。 二、议案审议情况 （一）审议通过《关于公司部分募投项目延期的议案》 1.议案内容： 具 体 内 容 详 见 公 司 于 同 日 在 北 京 证 券 交 易 所 官 方 ...

证券代码：836433 证券简称：大唐药业 公告编号：2023-004 内蒙古大唐药业股份有限公司 1 内蒙古大唐药业股份有限公司（以下简称"公司"）第三届董事会第十次 会议于2023年1月3日召开，根据《中华人民共和国公司法》（以下简称"《公司 法》"）《北京证券交易所股票上市规则（试行）》以及《内蒙古大唐药业股份 有限公司章程》（以下简称"《公司章程》"）和《内蒙古大唐药业股份有限公 司募集资金管理办法》（以下简称"《募集资金管理办法》"）及等法律、法规 及规章制度的有关规定，作为公司的独立董事，我们现对公司第三届董事会第 十次会议审议的以下议案发表如下独立意见： 一、《关于公司部分募投项目延期的议案》的独立意见 本次公司部分募投项目延期是公司根据"大唐药业健康科技产业园区项目" 实际情况做出的审慎决定，符合《公司法》《北京证券交易所股票上市规则 （试行）》以及《公司章程》和《募集资金管理办法》等的相关规定，审议程 序合法、合规。本次公司部分募投项目延期充分考虑了募集资金实际使用情况、 募投项目建设现状，不存在变相改变募集资金投向和损害股东利益的情形。 综上，我们同意《关于公司部分募投项目延期的议案》。 ...

内蒙古大唐药业股份有限公司 2022 年第三季度报告 证券代码：836433 证券简称：大唐药业 公告编号：2022-109 大唐药业 证券代码 : 836433 内蒙古大唐药业股份有限公司 2022 年第三季度报告 1 | 第一节 | 重要提示 4 | | --- | --- | | 第二节 | 公司基本情况 5 | | 第三节 | 重大事件 12 | | 第四节 | 财务会计报告 14 | 内蒙古大唐药业股份有限公司 2022 年第三季度报告 3 释义项目 释义 公司、本公司、股份公司、大唐药业 指 内蒙古大唐药业股份有限公司 仁和房地产 指 呼和浩特市仁和房地产开发有限公司 股东大会、董事会、监事会 指 股份公司股东大会、董事会、监事会 高级管理人员 指 公司总经理、副总经理、董事会秘书、财务总监以及《公 司章程》规定的人员 保荐机构、中泰证券 指 中泰证券股份有限公司 报告期 指 2022 年 7 月 1 日至 2022 年 9 月 30 日 本报告期初 指 2022 年 7 月 1 日 本报告期末 指 2022 年 9 月 30 日 上年同期 指 2021 年 7 月 1 日至 2021 年 9 月 ...

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 80,791,353.83, a decrease of 23.28% compared to CNY 105,302,839.15 in the same period last year[28]. - The net profit attributable to shareholders of the listed company was CNY 17,053,717.43, down 32.80% from CNY 25,377,387.53 year-on-year[28]. - The net profit after deducting non-recurring gains and losses was CNY 5,652,179.22, a significant decline of 76.04% compared to CNY 23,588,096.91 in the previous year[28]. - The gross profit margin increased to 77.91% from 74.54% year-on-year[28]. - The weighted average return on net assets based on net profit attributable to shareholders was 3.20%, down from 4.86% in the previous year[28]. - The company reported a basic earnings per share of CNY 0.06, a decrease of 64.71% compared to CNY 0.17 in the same period last year[28]. - The total operating income for the first half of 2022 was 78,368,000.00 CNY, with a year-on-year decrease of 25.17% in Northeast China and 14.07% in North China[51]. - The total comprehensive income for the period amounted to CNY 25,377,387.53[148]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 627,992,537.42, down 8.66% from CNY 687,534,613.17 at the end of the previous year[29]. - The total liabilities decreased by 5.94% to CNY 141,603,253.74 from CNY 150,553,281.42 year-on-year[29]. - Current assets totaled CNY 425,531,613.48 as of June 30, 2022, down from CNY 510,914,930.36 at the end of 2021, representing a decrease of approximately 16.7%[123]. - The company's equity attributable to shareholders decreased from CNY 536,981,331.75 to CNY 486,389,283.68, a decrease of about 9.4%[125]. - The total liabilities at the end of the period were not explicitly stated but can be inferred from the equity and asset figures[149]. Cash Flow - The company's cash flow from operating activities was CNY 52,540,997.56, a significant improvement from a negative cash flow of CNY -1,296,807.99 in the same period last year[29]. - The net cash flow from operating activities increased to approximately ¥52.54 million, a significant improvement from a negative cash flow of ¥1.30 million in the first half of 2021[139]. - The net cash flow from investment activities increased by 112,557,111.33 CNY, a significant improvement from -7,043,762.67 CNY in the previous period[55]. - The net cash flow from financing activities was -69,617,016.04 CNY, worsening from -22,229,088.61 CNY in the same period last year, primarily due to increased dividend payments[142]. Research and Development - The company has initiated several key R&D projects, including the "Research and Development of Quality Technical Standards for Classic Chinese-Mongolian Medicine" approved in May 2022[3]. - The company has received approval for the "Research and Industrialization of Generic Fluorometholone Liniment" project, indicating ongoing efforts in product development[3]. - Research and development expenses for the first half of 2022 were CNY 2,797,752.88, down from CNY 3,666,162.56 in the first half of 2021, a decrease of 23.7%[132]. Regulatory and Market Risks - The company is facing risks related to national regulatory policies, drug quality safety, and potential price reductions in the pharmaceutical market, which could impact revenue and profitability[10][11]. - The company is not currently required to conduct consistency evaluations for its products, but future regulatory changes could impose such requirements, affecting sales[12][13]. - The company anticipates a continued trend of drug price reductions in China, impacting revenue and profit margins[62]. - The company is adapting to the challenges and opportunities in the pharmaceutical industry, driven by ongoing healthcare reforms and increasing demand for high-quality pharmaceutical products[39]. Shareholder and Capital Structure - The company completed a cash dividend distribution of RMB 72,632,800.50, distributing RMB 5.00 per 10 shares and increasing the share capital by 116,212,480 shares[3]. - The total number of unrestricted shares increased from 70,009,589 to 169,177,685, representing a rise from 48.19% to 64.70% of total shares[85]. - The largest shareholder, Hohhot Renhe Real Estate Development Co., Ltd., holds 59.02% of the shares, increasing from 85,738,590 shares to 154,329,462 shares[89]. - The company has a commitment to avoid competition and has not engaged in any competitive activities with its subsidiaries, ensuring compliance with its commitments[81]. Employee and Management Changes - The company appointed two new senior executives: Lian Lijun as Executive Vice President and Liu Jia as Vice President, both effective from April and May 2022 respectively[112]. - Total employees increased from 213 to 232, with a net addition of 19 employees during the reporting period[116]. - Core employees decreased from 68 to 64, with 4 core employees leaving the company[118]. Corporate Governance and Compliance - The financial statements were approved by the board of directors on August 25, 2022[162]. - The company has evaluated its ability to continue as a going concern for the next 12 months and found no significant doubts regarding its sustainability[165]. - The company has not reported any significant asset impairment losses or changes in related party transactions during the reporting period[154].

Financial Performance - Operating revenue for Q1 2022 was CNY 28,484,733.38, representing a decline of 25.62% year-on-year[16] - Net profit attributable to shareholders for Q1 2022 was CNY 5,560,706.73, down 45.09% compared to the same period last year[16] - The net profit after deducting non-recurring gains and losses decreased by 59.02% year-on-year, amounting to CNY 3,713,600.84[16] - Basic earnings per share for Q1 2022 were CNY 0.04, a decrease of 42.86% from CNY 0.07 in Q1 2021[16] - Total operating revenue for Q1 2022 was CNY 28,484,733.38, a decrease of 25.6% compared to CNY 38,297,693.93 in Q1 2021[38] - The net profit for Q1 2022 was CNY 5,560,706.73, down 45.0% from CNY 10,126,885.66 in Q1 2021[40] - The total profit for Q1 2022 was CNY 6,388,303.95, a decline of 47.4% from CNY 12,138,509.83 in Q1 2021[40] - The total comprehensive income for Q1 2022 was CNY 5,560,706.73, a decrease of 45.0% compared to CNY 10,126,885.66 in Q1 2021[40] Cash Flow - The company's cash flow from operating activities was CNY 66,622,261.16, compared to a negative cash flow of CNY 13,814,864.56 in the previous year[16] - The cash inflow from operating activities for Q1 2022 was ¥104,649,776.57, a significant increase from ¥45,079,825.11 in Q1 2021, representing a growth of approximately 132.5%[45] - The net cash flow from operating activities for Q1 2022 was ¥66,622,261.16, compared to a negative cash flow of ¥13,814,864.56 in Q1 2021, indicating a turnaround in operational performance[45] - The total cash inflow from investment activities in Q1 2022 was ¥274,865,172.10, down from ¥382,313,126.27 in Q1 2021, reflecting a decrease of about 28.1%[47] - The net cash flow from investment activities for Q1 2022 was ¥166,654,874.13, a recovery from a negative cash flow of ¥4,024,025.47 in Q1 2021[47] - The cash inflow from financing activities in Q1 2022 was ¥7,247,400.00, a decrease from ¥25,672,750.00 in Q1 2021, showing a decline of approximately 71.7%[47] - The net increase in cash and cash equivalents for Q1 2022 was ¥228,605,661.83, compared to an increase of ¥7,519,488.08 in Q1 2021, indicating a substantial improvement[47] - The ending balance of cash and cash equivalents as of the end of Q1 2022 was ¥245,705,025.88, significantly higher than ¥75,837,833.33 at the end of Q1 2021[47] Assets and Liabilities - Total assets as of March 31, 2022, were CNY 679,354,800.06, a decrease of 1.19% compared to the end of 2021[16] - The asset-liability ratio for the consolidated entity was 20.04%, down from 21.90% at the end of 2021[16] - The total current assets decreased from 510,914,930.36 CNY on December 31, 2021, to 504,256,128.11 CNY on March 31, 2022[30] - The total liabilities decreased from 145,452,319.77 CNY on December 31, 2021, to 131,179,914.74 CNY on March 31, 2022[31] - The company's fixed assets are valued at 86,066,798.79 CNY as of March 31, 2022, down from 88,030,062.33 CNY at the end of 2021[31] - Total liabilities decreased to CNY 135,112,924.39 in Q1 2022 from CNY 149,145,017.47 in Q1 2021, reflecting a reduction of 9.4%[36] - Shareholders' equity increased to CNY 541,645,436.67 in Q1 2022 from CNY 534,641,447.45 in Q1 2021, representing a growth of 1.9%[36] Shareholder Information - The number of ordinary shareholders was 12,888 as of the report date[22] - The largest shareholder, Hohhot Renhe Real Estate Development Co., Ltd., holds 85,738,590 shares, representing 59.02% of total shares[24] - The total shares held by the top ten shareholders amount to 98,258,941, which is 67.63% of the total shares[24] Operational Challenges - The company experienced a significant decline in sales due to reduced foot traffic in pharmacies and outpatient volumes in hospitals caused by the domestic pandemic[17] Research and Development - Research and development expenses increased to CNY 1,487,606.90 in Q1 2022, up 26.9% from CNY 1,171,860.85 in Q1 2021[40] Other Financial Metrics - The company's financial expenses rose significantly to CNY 800,522.41 in Q1 2022, compared to CNY 174,826.76 in Q1 2021[40] - Investment income for Q1 2022 was CNY 2,286,784.99, down 53.5% from CNY 4,913,126.27 in Q1 2021[40] - The company's sales expenses were CNY 11,928,031.13 in Q1 2022, slightly down from CNY 12,440,021.79 in Q1 2021[40] - The company's management expenses decreased to CNY 5,420,978.24 in Q1 2022 from CNY 5,618,307.52 in Q1 2021[40]

Financial Performance - The company's operating revenue for 2021 was CNY 235,878,772.67, representing an increase of 8.25% compared to CNY 217,899,726.83 in 2020[33]. - The net profit attributable to shareholders for 2021 was CNY 61,945,412.84, which is a 1.81% increase from CNY 60,843,631.55 in 2020[33]. - The gross profit margin improved to 74.90% in 2021 from 70.93% in 2020[33]. - The company's net profit growth rate for 2021 was 1.81%, compared to a growth rate of 12.23% in 2020[38]. - The company achieved a revenue of 235.88 million yuan in 2021, representing an increase of 8.25% compared to the previous year[52]. - The net profit for 2021 was 61.95 million yuan, which is a growth of 1.81% year-on-year, primarily driven by the increase in revenue[52]. - The company's cash flow from operating activities decreased significantly by 87.74% to CNY 11,782,297.68 in 2021 from CNY 96,083,470.86 in 2020[37]. - The weighted average return on equity (ROE) based on net profit attributable to shareholders was 11.83% in 2021, down from 17.30% in 2020[33]. - The basic earnings per share for 2021 was CNY 0.43, a decrease of 14.00% from CNY 0.50 in 2020[33]. - The total revenue for Inner Mongolia Datang Pharmaceutical Co., Ltd. increased by 8.25% year-on-year, with main business revenue growing by 12.02% due to increased product sales[73]. Assets and Liabilities - Total assets increased by 5.67% to CNY 687,534,613.17 at the end of 2021, compared to CNY 650,660,548.98 at the beginning of the year[35]. - The total liabilities rose by 12.55% to CNY 150,553,281.42 at the end of 2021, up from CNY 133,761,583.42 at the beginning of the year[35]. - The company reported a total of CNY 1,062,200,000.00 in financial products, with no overdue amounts or expected impairments[86]. - The total value of pledged assets amounts to 59,556,890.86 CNY, representing 8.66% of total assets[147]. Research and Development - The company holds 19 patents, including 3 invention patents, supporting its competitive edge in the pharmaceutical industry[49]. - Research and development expenses grew by 41.52%, reflecting an increase in R&D projects[66]. - The company reported a total R&D expenditure of ¥7,388,334.03, representing 3.13% of operating revenue, an increase from 2.40% in the previous year[94]. - The company has established collaborations with Tianjin University of Traditional Chinese Medicine and China Pharmaceutical University for various research projects[99]. - The company is addressing potential R&D delays by collaborating with external experts to ensure timely execution of its R&D strategies[114]. Market and Sales Strategy - The company aims to enhance its marketing system and brand promotion to expand market coverage and improve brand recognition[54]. - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development efforts[182]. - The company is positioned within the pharmaceutical manufacturing sector, benefiting from macroeconomic growth and increasing healthcare demands[195]. - The company is adapting to national procurement policies aimed at promoting innovation within the pharmaceutical industry[196]. - The company continues to focus on expanding its market presence through both distribution and academic promotion strategies[200]. Risks and Challenges - The company faces risks related to the fluctuation of raw material prices, which can directly impact production costs and operating profits[15]. - The company’s products are subject to government pricing regulations, and recent trends indicate a continued decline in drug prices, which may affect revenue and profit[15]. - The company reported a significant risk related to the impact of the COVID-19 pandemic on offline marketing activities and rising costs, including raw materials, labor, and logistics[16]. - The company is managing raw material price volatility by establishing stable supplier relationships and maintaining flexible inventory control[119]. - The company anticipates ongoing price reductions in the pharmaceutical market and is strengthening its OTC sales channels to mitigate this risk[118]. Corporate Governance - The company has established a compensation and assessment committee responsible for formulating and reviewing the compensation policies for directors and senior management[183]. - The company’s management team remains stable, with no changes in the chairman, general manager, or financial director during the reporting period[179]. - The company experienced changes in its board, with new appointments including Zhang Jian as an independent director and Zhao Fenrong as a supervisor[180]. - Independent directors receive a pre-tax allowance of CNY 65,000 per year[183]. Shareholder Information - The total number of shares held by the top ten shareholders is 98,454,793, accounting for 67.76% of the total shares[155]. - The largest shareholder, Hohhot Renhe Real Estate Development Co., Ltd., holds 85,738,590 shares, representing 59.02% of the total shares[155]. - The company raised a total of 289,598,400 yuan through public offerings, with 64,087,698.99 yuan utilized during the reporting period[165]. - The company has not changed the use of raised funds and has complied with all relevant regulations regarding fund usage[166]. Employee Information - The total number of employees decreased from 219 at the beginning of the period to 213 at the end, with a net reduction of 6 employees[187]. - The number of technical personnel increased from 44 to 47, reflecting a net addition of 3 employees in this category[187]. - The company has implemented a complete training program, enhancing employee skills through various training initiatives[188]. - The company has established a comprehensive compensation and performance evaluation system to attract and retain talent, ensuring competitive salary levels in the industry[188].